5月8日 - ** Artiva Biotherapeutics ARTV.O 股价在盘前交易中上涨 25%，至 14.02 美元
** 这家生物技术公司表示，其疗法AlloNK针对类风湿性关节炎——一种由免疫系统攻击关节引起的疾病；6个月时71%的患者出现显著改善
** 无患者复发或需要额外免疫药物；该疗法耐受性良好，未出现严重副作用——ARTV
** 补充称，美国FDA已批准一项晚期临床试验，将对约150名患者进行AlloNK联合利妥昔单抗与单用利妥昔单抗的对比研究；该试验将于2026年下半年启动
** 研究还显示该疗法对舍格伦综合征(干眼/口干) 及系统性硬化症(皮肤增厚) 具有疗效
** 称该疗法通过减少驱动自身免疫性疾病的B细胞发挥作用
** 截至上一交易日收盘，该股年内涨幅已超两倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.